Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Sireen Abdul Rahim Shilbayeh & Sahar Abd El Rahman Ismail. (2020) Patient experience with an educational mobile health application: A pilot study on usability and feasibility in a Saudi population. Cogent Psychology 7:1.
Read now
Read now
Kevin Bowrin, Jean-Baptiste Briere, Pierre Levy, Mondher Toumi & Aurélie Millier. (2020) Use of real-world evidence in meta-analyses and cost-effectiveness models. Journal of Medical Economics 23:10, pages 1053-1060.
Read now
Read now
Jennifer L Koehl, Bryan D. Hayes, Hanny Al‐Samkari & Rachel Rosovsky. (2020) A comprehensive evaluation of apixaban in the treatment of venous thromboembolism. Expert Review of Hematology 13:2, pages 155-173.
Read now
Read now
Kevin Bowrin, Jean-Baptiste Briere, Pierre Levy, Aurélie Millier, Jean Tardu & Mondher Toumi. (2020) Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK. Journal of Market Access & Health Policy 8:1.
Read now
Read now
Jean-Baptiste Briere, Kevin Bowrin, Aurélie Millier, Mondher Toumi, Piotr Wojciechowski & Vanessa Taieb. (2019) Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation. Journal of Medical Economics 22:8, pages 760-765.
Read now
Read now
Craig I. Coleman, Jean-Baptiste Briere, Laurent Fauchier, Pierre Levy, Kevin Bowrin, Mondher Toumi, Aurélie Millier, Vanessa Taieb & Olivia Wu. (2019) Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. Journal of Market Access & Health Policy 7:1.
Read now
Read now
Articles from other publishers (9)
Josep Comín Colet, Antoni Sicras Mainar, Joel Salazar-Mendiguchía, María Isabel del Campo Alonso, Ainara Echeto, David Vilanova Larena & Olga Delgado Sánchez. (2023) Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol. Journal of Comparative Effectiveness Research 12:8.
Crossref
Crossref
Wataru Shimizu, Shinichiro Uchiyama, Hirotsugu Atarashi, Hiroshi Inoue, Takanari Kitazono, Takeshi Yamashita, Takanori Ikeda, Masahiro Kamouchi, Koichi Kaikita, Koji Fukuda, Hideki Origasa & Hiroaki Shimokawa. (2023) Effectiveness and safety of reduced-dose rivaroxaban for elderly patients with non-valvular atrial fibrillation: A subanalysis of the EXPAND study. International Journal of Cardiology, pages 131290.
Crossref
Crossref
Manon Belhassen, Olivier Hanon, Philippe Gabriel Steg, Isabelle Mahé, Mélanie Née, Flore Jacoud, Faustine Dalon, François-Emery Cotté, Dominique Guitard-Dehoux, Claire Marant-Micallef, Eric Van Ganse & Nicolas Danchin. (2022) Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France. The European Journal of Health Economics 24:6, pages 867-875.
Crossref
Crossref
Simon de Lusignan, F. D. Richard Hobbs, Harshana Liyanage, Julian Sherlock, Filipa Ferreira, Manasa Tripathy, Christian Heiss, Michael Feher & Mark P. Joy. (2022) Long term follow up of direct oral anticoagulants and warfarin therapy on stroke, with all-cause mortality as a competing risk, in people with atrial fibrillation: Sentinel network database study. PLOS ONE 17:9, pages e0265998.
Crossref
Crossref
Jean Jacques Noubiap & Joseph Kamtchum‐Tatuene. (2022) Addition of direct oral anticoagulants to the World Health Organization model list of essential medicines for the treatment of atrial fibrillation: An African perspective. British Journal of Clinical Pharmacology 88:7, pages 3035-3038.
Crossref
Crossref
Carlos Escobar Cervantes, Julio Martí-Almor, Alejandro Isidoro Pérez Cabeza, Kevin Bowrin, Aleix Llorac Moix, Mar Genís Gironès, David Gasche, Aurélie Millier, Jean Tardu, Mondher Toumi & Jean-Baptiste Briere. (2022) Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain. PLOS ONE 17:4, pages e0266658.
Crossref
Crossref
Edwige Lorthiois, James Roache, David Barnes-Seeman, Eva Altmann, Ulrich Hassiepen, Gordon Turner, Rohit Duvadie, Viktor Hornak, Rajeshri G. Karki, Nikolaus Schiering, Wilhelm A. Weihofen, Francesca Perruccio, Amy Calhoun, Tanzina Fazal, Darija Dedic, Corinne Durand, Solene Dussauge, Kamal Fettis, Fabien Tritsch, Celine Dentel, Adelaide Druet, Donglei Liu, Louise Kirman, Julie Lachal, Kenji Namoto, Douglas Bevan, Rose Mo, Gabriela Monnet, Lionel Muller, Richard Zessis, Xueming Huang, Loren Lindsley, Treeve Currie, Yu-Hsin Chiu, Cary Fridrich, Peter Delgado, Shuangxi Wang, Micah Hollis-Symynkywicz, Joerg Berghausen, Eric Williams, Hong Liu, Guiqing Liang, Hyungchul Kim, Peter Hoffmann, Andreas Hein, Paul Ramage, Allan D’Arcy, Stefanie Harlfinger, Martin Renatus, Simon Ruedisser, David Feldman, Jason Elliott, Richard Sedrani, Juergen Maibaum & Christopher M. Adams. (2020) Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach. Journal of Medicinal Chemistry 63:15, pages 8088-8113.
Crossref
Crossref
Larisa Anghel, Radu Sascău, Anca Trifan, Ioana Mădălina Zota & Cristian Stătescu. (2020) Non-Vitamin K Antagonist Oral Anticoagulants and the Gastrointestinal Bleeding Risk in Real-World Studies. Journal of Clinical Medicine 9:5, pages 1398.
Crossref
Crossref
Sreeram V Ramagopalan, Antoni Sicras-Mainar, Carlos Polanco-Sanchez, Robert Carroll & Jaime F de Bobadilla. (2019) Patient characteristics and stroke and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban and vitamin K antagonists: a Spanish real-world study. Journal of Comparative Effectiveness Research 8:14, pages 1201-1212.
Crossref
Crossref